Journal: Journal of Veterinary Diagnostic Investigation : Official Publication of the American Association of Veterinary Laboratory Diagnosticians, Inc

Article Title: Activated platelets and platelet-leukocyte aggregates in the equine systemic inflammatory response syndrome

doi: 10.1177/10406387221077969

Figure Lengend Snippet: Percentages of activated platelets (CD62P-positive) and platelet-leukocyte aggregates (PLAs; CD11a/18-positive) in platelet-leukocyte-rich plasma (PLRP) and after activation with collagen (50 μg/mL) measured with Accuri C6 (Becton Dickinson) and the BD Accuri C6 analysis software in 10 healthy adult horses (median, IQR; Prism v.6, GraphPad; Wilcoxon test).

Article Snippet: Activation of platelets was determined with fluorescein isothiocyanate (FITC)-conjugated (LYNX rapid antibody conjugation kit; Bio-Rad) monoclonal mouse anti-human antibodies against CD62P (MCA2419, dilution 1:50 with modified HEPES/Tyrod buffer).

Techniques: Activation Assay, Software

Journal: Journal of Veterinary Diagnostic Investigation : Official Publication of the American Association of Veterinary Laboratory Diagnosticians, Inc

Article Title: Activated platelets and platelet-leukocyte aggregates in the equine systemic inflammatory response syndrome

doi: 10.1177/10406387221077969

Figure Lengend Snippet: Platelet activation and platelet-leukocyte aggregates (PLAs) in controls ( n = 10) and systemic inflammatory response syndrome (SIRS) group ( n = 17) in native samples (white boxes) and after in vitro activation with collagen (cross-hatched boxes); boxes are median and IQR, whiskers minimum and maximum. A. Percentage of CD62P-positive platelets; a, p = 0.0007; b, p < 0.0001. B. Percentage of PLAs: c, p = 0.048; d, p = 0.0009; e, p = 0.036.

Article Snippet: Activation of platelets was determined with fluorescein isothiocyanate (FITC)-conjugated (LYNX rapid antibody conjugation kit; Bio-Rad) monoclonal mouse anti-human antibodies against CD62P (MCA2419, dilution 1:50 with modified HEPES/Tyrod buffer).

Techniques: Activation Assay, In Vitro

Journal: Journal of Veterinary Diagnostic Investigation : Official Publication of the American Association of Veterinary Laboratory Diagnosticians, Inc

Article Title: Activated platelets and platelet-leukocyte aggregates in the equine systemic inflammatory response syndrome

doi: 10.1177/10406387221077969

Figure Lengend Snippet: Platelet activation and platelet-leukocyte aggregates (PLAs) in the systemic inflammatory response syndrome (SIRS) group ( n = 13) depending on outcome in native samples (open circles) and after in vitro activation with collagen (black dots); bar = median. A. Individual percentage of CD62P-positive platelets; a, p = 0.03. B. Individual percentage of PLAs.

Article Snippet: Activation of platelets was determined with fluorescein isothiocyanate (FITC)-conjugated (LYNX rapid antibody conjugation kit; Bio-Rad) monoclonal mouse anti-human antibodies against CD62P (MCA2419, dilution 1:50 with modified HEPES/Tyrod buffer).

Techniques: Activation Assay, In Vitro

Journal: Asian journal of pharmaceutical sciences

Article Title: Fucoidan-based dual-targeting mesoporous polydopamine for enhanced MRI-guided chemo-photothermal therapy of HCC via P-selectin-mediated drug delivery.

doi: 10.1016/j.ajps.2022.08.004

Figure Lengend Snippet: Fig. 4 – In vivo targeting ability and MRI performance. (A) In vivo biodistribution of MPDA/Gd 3 + /ICG or FMPDA/Gd 3 + /ICG in the tumor-bearing mice model, and the marked red circle indicates the tumor site. Ex vivo images (B) and the corresponding average signal intensity (C) of the tumor tissue and major organs harvested at 24 h post-injection. (D) Fluorescent images of tumor frozen sections harvested at 24 h post-injection, in which the tumor tissue was stained with DAPI and anti-CD41 antibody, respectively. (E) Fluorescent images of tumor frozen sections harvested at 24 h post-injection, in which the tumor tissue was stained with DAPI and P-selectin antibody, respectively. In vivo T1-weighted images (F) and relative T 1 MRI signal intensity (G) of tumors treated before and after treating with MPDA/Gd 3 + /DOX or FMPDA/Gd 3 + /DOX. ( ∗P < 0.05, n = 3).

Article Snippet: AntiD62P (P-selectin) antibody was purchased from Boster Co., td. (Wuhan, China).

Techniques: In Vivo, Ex Vivo, Injection, Staining

Journal: Asian journal of pharmaceutical sciences

Article Title: Fucoidan-based dual-targeting mesoporous polydopamine for enhanced MRI-guided chemo-photothermal therapy of HCC via P-selectin-mediated drug delivery.

doi: 10.1016/j.ajps.2022.08.004

Figure Lengend Snippet: Scheme 1 – In this work, FMDA/Gd 3 + /DOX was prepared for enhanced cancer theranostics. Due to the specific binding ability between fucoidan and p-selectin, this novel theranostic agent could effectively accumulate into tumor site by simultaneously targeting to the activated paltelets and tumor cells, thereby resulting in an enhanced MRI-guided chemo-photothermal combination therapy of HCC.

Article Snippet: AntiD62P (P-selectin) antibody was purchased from Boster Co., td. (Wuhan, China).

Techniques: Binding Assay

Journal: Asian Journal of Pharmaceutical Sciences

Article Title: Fucoidan-based dual-targeting mesoporous polydopamine for enhanced MRI-guided chemo-photothermal therapy of HCC via P-selectin-mediated drug delivery

doi: 10.1016/j.ajps.2022.08.004

Figure Lengend Snippet: In vitro targeting ability and anti-cancer evaluation. (A) CLSM images of thrombin-activated and non-activated platelets treated with FMPDA/Gd 3+ /DOX or MPDA/Gd 3+ /DOX for 30 min. In the case of competitive assay, thrombin-activated platelets were pretreated with Anti-CD62P antibody for 30 min. (B) CLSM images of LM3 cells treated with FMPDA/Gd 3+ /DOX or MPDA/Gd 3+ /DOX for 1 h or 6 h, respectively. In the case of competitive assay, LM3 cells were pretreated with Anti-CD62P antibody for 30 min. (C) CLSM images of LM3 cells after incubating with FMPDA/Gd 3+ /DOX or MPDA/Gd 3+ /DOX for 1 h, in the presence of absence of the activated platelets. (D) The cell viability of LM3 cells treated with free DOX, MPDA/Gd 3+ /DOX or FMPDA/Gd 3+ /DOX at different DOX dose for 48 h. (E) The cell viability of LM3 cells treated with different concentrations of FMPDA/Gd 3+ or FMPDA/Gd 3+ /DOX for 12 h, followed by the treatment with or without NIR irradiation (2 W/cm 2 , 5 min) and then incubation for another 2 h. (F) The fluorescent images of survival LM3 cells in different treatment groups (MPDA= 80 µg/ml). (* P < 0.05, ** P < 0.01, *** P < 0.001, **** P <0.0001, n = 5).

Article Snippet: Anti-CD62P (P-selectin) antibody was purchased from Boster Co., Ltd. (Wuhan, China).

Techniques: In Vitro, Irradiation, Incubation

Journal: Asian Journal of Pharmaceutical Sciences

Article Title: Fucoidan-based dual-targeting mesoporous polydopamine for enhanced MRI-guided chemo-photothermal therapy of HCC via P-selectin-mediated drug delivery

doi: 10.1016/j.ajps.2022.08.004

Figure Lengend Snippet: In vivo targeting ability and MRI performance. (A) In vivo biodistribution of MPDA/Gd 3+ /ICG or FMPDA/Gd 3+ /ICG in the tumor-bearing mice model, and the marked red circle indicates the tumor site. Ex vivo images (B) and the corresponding average signal intensity (C) of the tumor tissue and major organs harvested at 24 h post-injection. (D) Fluorescent images of tumor frozen sections harvested at 24 h post-injection, in which the tumor tissue was stained with DAPI and anti-CD41 antibody, respectively. (E) Fluorescent images of tumor frozen sections harvested at 24 h post-injection, in which the tumor tissue was stained with DAPI and P-selectin antibody, respectively. In vivo T1-weighted images (F) and relative T 1 MRI signal intensity (G) of tumors treated before and after treating with MPDA/Gd 3+ /DOX or FMPDA/Gd 3+ /DOX. (* P < 0.05, n = 3).

Article Snippet: Anti-CD62P (P-selectin) antibody was purchased from Boster Co., Ltd. (Wuhan, China).

Techniques: In Vivo, Ex Vivo, Injection, Staining

Journal: Asian Journal of Pharmaceutical Sciences

Article Title: Fucoidan-based dual-targeting mesoporous polydopamine for enhanced MRI-guided chemo-photothermal therapy of HCC via P-selectin-mediated drug delivery

doi: 10.1016/j.ajps.2022.08.004

Figure Lengend Snippet: In this work, FMDA/Gd 3+ /DOX was prepared for enhanced cancer theranostics. Due to the specific binding ability between fucoidan and p-selectin, this novel theranostic agent could effectively accumulate into tumor site by simultaneously targeting to the activated paltelets and tumor cells, thereby resulting in an enhanced MRI-guided chemo-photothermal combination therapy of HCC.

Article Snippet: Anti-CD62P (P-selectin) antibody was purchased from Boster Co., Ltd. (Wuhan, China).

Techniques: Binding Assay